Bugs & Drugs

I found that I was losing the plot about what was where! Here’s my quick guide to priority pathogens (just below) and pipeline reviews. Note in particular that a comparative Summary of the priority pathogens lists is provided. For my summary of incentives to support this pipeline, see this webpage. Corrections and amends gratefully received.

Priority Pathogen / Threat Lists

  • By my count, five priority pathogen lists have been proposed / published to date:
    1. India 2021: Newsletter is here, report is here.
    2. CDC 2019: Newsletter is here, report itself is here.
    3. WHO 2017: Newsletter is here, report itself is here.
    4. CDC 2013: Report itself is here.
    5. ESKAPE list 2008-9: This is the grandfather/mother of them all! The original papers are here:
      • (link) Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis. 2008;197(8):1079-81.
      • (link) Boucher HW et al. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. Clinical Infectious Diseases. 2009;48(1):1-12

To help you keep them organized, a comparative summary of the priority pathogen lists as a PowerPoint deck is here.

  • Please also see this newsletter for a further discussion of the priority pathogen lists as well as the idea of first- vs. best-in-class.

Pipeline Reviews

  • Reviews by WHO
    • WHO 2020: My newsletter is here (and includes a video chat with Peter Beyer, one of the key drivers of the report). The review itself is here.
    • WHO 2019: My newsletter is here, commentary by WHO staff is here, the pre-clinical pipeline review is here and is supported by a data-mining interface here; the clinical pipeline review is here.
    • WHO 2017: Newsletter is here, report is here, and manuscript about the review is here.
  • Reviews by the Pew Trusts (all updated as of March 2021; see also this newsletter)
    • Go here for traditional therapeutics.
    • Go here for a visualization of pipeline changes during 2014-2020.
    • Non-traditional products are separately summarized here.
  • Independent pipeline reviews
  • Access- and Stewardship-focused reviews
    • CDDEP’s “The State of the World’s Antibiotics Report in 2021” (link) presents extensive data on global antimicrobial use and resistance, a brief pipeline review, and by-country dashboards
    • ATMF’s “2021 Access to Medicine Index” (link) summarizes progress made and work to be done on access.

Consultancy: Sustainability framework for off-patent antibiotics // The Third Man

Dear All, I have just learned that the AMR Industry Alliance has posted an RFP for a consultant to support the work of its Access Working Group with applications for the RFP due 24 September 2021. The consultancy project focuses on the root causes of (or lack thereof!) supply chain resilience for off-patent antibiotics, including stockouts, shortages

Outstanding discussions of Pull, the NHS Pilot, and Antibiotic value

Dear All, The BEAM Alliance, along with its partners (CARB-X, the Novo REPAIR Impact Fund, the IMI AMR Accelerator, and the European Biotechnology Magazine) converted their annual AMR conference into a virtual event held 24-26 Aug 2021. As usual, it was excellent! I know we’re all really, REALLY tired of virtual meetings but the 2h/day x 3 day themed format worked well:

Scroll to Top